Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 7681 results

  1. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

    In development [GID-TA11203] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  2. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    Medical technologies guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for MTG43

  3. Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

    Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.

    Medical technologies guidance
    Published
    7 June 2019
    View recommendations

    Sections for MTG45

  4. gammaCore for cluster headache (MTG46)

    Evidence-based recommendations on gammaCore for cluster headache.

    Medical technologies guidance
    Published
    3 December 2019
    View recommendations

    Sections for MTG46

  5. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

    Medical technologies guidance
    Published
    23 January 2019
    View recommendations

    Sections for MTG41

  6. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

    Medical technologies guidance
    Last updated
    4 April 2023
    View recommendations

    Sections for MTG42

  7. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

    Medical technologies guidance
    Last updated
    18 September 2019
    View recommendations

    Sections for MTG25

  8. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  9. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

    In development [GID-TA11288] Expected publication date: 23 April 2025

    Technology appraisal guidance
    In development

  10. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  11. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development [GID-TA11303] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  13. Slide sheets for repositioning or moving a person on or from a bed: Late Stage Assessment

    In development [GID-HTE10051] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  14. Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217

    Awaiting development [GID-TA11192] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer ID6481

    Awaiting development [GID-TA11607] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development